CRISPR/Cas9 for cancer research and therapy
CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
Seminars in cancer biology
Year: 2018, Jahrgang: 55, Pages: 106-119 |
| ISSN: | 1096-3650 |
| DOI: | 10.1016/j.semcancer.2018.04.001 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.semcancer.2018.04.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1044579X17302742 
|
| Verfasserangaben: | Tianzuo Zhan, Niklas Rindtorff, Johannes Betge, Matthias P. Ebert, Michael Boutros |
| Zusammenfassung: | CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer. |
|---|---|
| Beschreibung: | Available online 16 April 2018 Gesehen am 27.05.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1096-3650 |
| DOI: | 10.1016/j.semcancer.2018.04.001 |